Human Pathology
Volume 34, Issue 1 , Pages 48-53 , January 2003

Expression of p27KIP1 in human gliomas: Relationship between tumor grade, proliferation index, and patient survival

,Accepted 11 September 2002.

References 

  1. Steeg PS, Abrams JS. Cancer prognostics: Past, present and p27. Nat Med. 1997;3:152–154
  2. Slingerland J, Pagano M. Regulation of the Cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000;183:10–17
  3. Lloyd RV, Erickson LA, Jin L, et al.  p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 1999;154:313–323
  4. Porter PL, Malone KE, Heagerty PJ, et al.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997;3:222–225
  5. Catzavelos C, Bhattacharya N, Ung YC, et al.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nat Med. 1997;3:227–230
  6. Mori M, Mimori K, Shiraishi T, et al.  p27 expression and gastric carcinoma. Nat Med. 1997;3:593
  7. Cordon-Cardo C, Koff A, Drobnjak M, et al.  Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst. 1998;90:1284–1291
  8. Kawana H, Tamaru J, Tanaka T, et al.  Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol. 1998;153:505–513
  9. Newcomb EW, Sosnow M, Demopoulos RI, et al.  Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol. 1999;154:119–125
  10. Loda M, Cukor B, Tam SW, et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231–234
  11. Thomas GV, Szigeti K, Murphy M, et al.  Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol. 1998;153:681–687
  12. Palmqvist R, Stenling R, Oberg A, et al.  Prognostic significance of p27(Kip1) expression in colorectal cancer: A clinico-pathological characterization. J Pathol. 1999;188:18–23
  13. Lloyd RV, Jin L, Qian X, et al.  Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol. 1997;150:401–407
  14. Jordan RC, Bradley G, Slingerland J. Reduced levels of the cell-cycle inhibitor p2Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol. 1998;152:585–590
  15. Pagano M, Tam SW, Theodoras AM, et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269:682–685
  16. Piva R, Cavalla P, Bortolotto S, et al.  p27/kip1 expression in human astrocytic gliomas. Neurosci Lett. 1997;234:127–130
  17. Piva R, Cancelli I, Cavalla P, et al.  Proteasome-dependent degradation of p27/kip1 in gliomas. J Neuropathol Exp Neurol. 1999;58:691–696
  18. Mizumatsu S, Tamiya T, Ono Y, et al.  Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma. Clin Cancer Res. 1999;5:551–557
  19. Fuse T, Tanikawa M, Nakanishi M, et al.  p27Kip1 expression by contact inhibition as a prognostic index of human glioma. J Neurochem. 2000;74:1393–1399
  20. Ehrmann J, Collan Y, Rihakova P, et al.  Apoptosis, analyzed by means of lamin B detection, correlates with grade of astroglial tumours but not with p27kip1/retinoblastoma protein expression. Virchows Arch. 2001;439:547–551
  21. Naumann U, Weit S, Rieger L, et al.  p27 modulates cell cycle progression and chemosensitivity in human malignant glioma. Biochem Biophys Res Commun. 1999;261:890–896
  22. Nakasu S, Nakajima M, Handa J. Anomalous p27Kip1 expression in a subset of malignant gliomas. Brain Tumor Pathol. 1999;16:17–21
  23. Alleyne CH, He J, Yang J, et al.  Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas. Int J Oncol. 1999;14:1111–1116
  24. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3:255–268
  25. Zagzag D, Friedlander DR, Miller DC, et al.  Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res. 1995;55:907–914
  26. Yatabe Y, Masuda A, Koshikawa T, et al.  p27KIP1 in human lung cancers: Differential changes in small cell and non-small cell carcinomas. Cancer Res. 1998;58:1042–1047
  27. Masuda A, Osada H, Yatabe Y, et al.  Protective function of p27KIP1 against apoptosis in small cell lung cancer cells in unfavorable microenvironments. Am J Pathol. 2001;158:87–96
  28. Zagzag D, Zhong H, Scalzitti JM, et al.  Expression of hypoxia-inducible factor 1α in human brain tumors: Association with angiogenesis, invasion and progression. Cancer. 2000;88:2606–2618
  29. Carmeliet P, Dor Y, Herbert JM, et al.  Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394:485–490
  30. Gardner LB, Li Q, Park MS, et al.  Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem. 2001;276:7919–7926
  31. Krtolica A, Krucher NA, Ludlow JW. Molecular analysis of selected cell cycle regulatory proteins during aerobic and hypoxic maintenance of human ovarian carcinoma cells. Br J Cancer. 1999;80:1875–1883
  32. Fujii T, Otsuki T, Moriya T, et al.  Effect of hypoxia on human seminoma cells. Int J Oncol. 2002;20:955–962
  33. Newcomb EW, Cohen H, Lee SR, et al.  Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. 1998;8:655–667
  34. Daumas-Duport C, Scheithauer BW, Kelly PJ. A histologic and cytologic method for the spatial definition of gliomas. Mayo Clin Proc. 1987;62:435–449
  35. Cunningham JM, Kimmel DW, Scheithauer BW, et al.  Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationships and prognostic value. J Neurosurg. 1997;86:121–130
  36. Pomeroy S, Tamayo P, Gaasenbeek M, et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415:436–442

☆ Supported in part by American Cancer Society grant RPG-00-060-01-CCE (D.Z.) and National Institutes of Health grant RO1CA90290 (E.W.N.).

☆☆ Address correspondence and reprint requests to David Zagzag, MD, PhD, Department of Pathology, New York University School of Medicine, 550 First Avenue, New York, NY 10016.

PII: S0046-8177(03)00009-1

doi: 10.1053/hupa.2003.54

Human Pathology
Volume 34, Issue 1 , Pages 48-53 , January 2003

Article Tools

* Image Usage & Resolution